Targeted Oncology

Checkpoint Inhibitors in Lung Cancer: When One Drug Isn't Enough

Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
ascopubs.org

Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non–Small Cell Lung Cancer Management With Cemiplimab

Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...
Medscape

Ivonescimab: Possible New First-Line Standard in PD-L1-Positive Advanced NSCLC?

First-line treatment with ivonescimab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients ...
FiercePharma

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific ...